Drug-adapted cancer cell lines as preclinical models of acquired resistance
Explore this paper's citation graph
Summary
It is argued that drug-adapted cancer cell lines represent a preclinical model system in their own right that is complementary to other pre clinical model systems and clinical data.
- Type
- review
- Published
- 2019-06-26
- Cited by
- 43
- References
- 123
- Access
- Open access
- OpenAlex
- https://openalex.org/W2953531917
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:198278154
Keywords
Drug resistance, Acquired resistance, Cancer, Medicine, Clinical trial
References
- Acquired MET Expression Confers Resistance to EGFR Inhibition In a Mouse Model of Glioblastoma Multiforme
- Multidrug resistance in relapsed AML: Evidence of biological heterogeneity
- Guidelines for the use of cell lines in biomedical research
- Patient-derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer
- MDM2, MDMX and p53 in oncogenesis and cancer therapy
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
- Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
- Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
- Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer
- The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation
- In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
- Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.
- Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents
- Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch-and Hedgehog-Dependent Tumor-Initiating Cells
- Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.
Cited by
- SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine
- Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy
- Towards image-based cancer cell lines authentication using deep neural networks
- Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
- Mapping cisplatin-induced viscosity alterations in cancer cells using molecular rotor and fluorescence lifetime imaging microscopy
- Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis
- Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
- Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy.
- Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate Cancer cell lines.
- CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity.
- Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy
- Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
- Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer
- Changes in intracellular activation-related gene expression and induction of Akt contribute to acquired resistance toward nelarabine in CCRF-CEM cell line
- Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
- Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells
- Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells
- ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein
- Increased HRD score in cisplatin resistant penile cancer cells
- Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy
Related papers
- People's Drug Guide to Deadly Drug Interactions Focuses on Drug/Drug, Drug/Food, and Drug/Vitamin Interactions:
- Me-too drug,me-better drug and me-new drug in drug R&D
- A Watershed Role of the Central Office of Investigator-initiated Clinical Trial in Cardiovascular Fields
- Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets
- Antagonistic drug combinations that select against drug resistance: From bacteria to cancer
- Intrinsic and Acquired Drug Resistance in Malignant Tumors
- Drug resistance in cancer: an overview of the clinical aspects.